Leadership
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
Parking and security at the FDA’s White Oak headquarters were strained from the influx of employees who had to report to work in person on 17 March.
The Health and Human Services Department's decision to eliminate the Richardson Waiver may be a blow for transparency, but will not completely eliminate scrutiny of regulations, experts said.
Industry likely wants Grace Graham to take the FDA’s top policy and legislative role, but she may be passed over for someone more tied to HHS Secretary Robert F. Kennedy Jr.’s interests.
Veteran pharma executive leads Vitamin Angels; CEO change to lead unifying Dr. Scholl's brand worldwide; and first CEO change for Prinova in 42 years.
The $25,000 buyout, in addition to the early retirement program and layoffs, is intended to reduce the size of the HHS workforce.
HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.
HELP Committee members pepper Martin Makary with questions about his investments and potential conflicts of interest as commissioner. Makary’s transparency extends to saying FDA should “use common sense to ask some big questions we've never asked before,” including making more medical products available OTC.
The Voluntary Early Retirement Authority (VERA) plan would make many FDA employees with 20 or more years of service eligible for retirement, potentially increasing senior staff departures as the agency develops more layoff plans.
Advercheck managing director James Walmsley talks to HBW Insight about the challenges facing consumer health companies today as they move away from the prescription medicines sector and its pipeline of switchable ingredients towards self-care and prevention.
Kyle Diamantas was a partner with the Jones Day firm when he was tabbed as acting deputy commissioner to lead the FDA’s Human Foods Program, established in the agency’s reorganization which became effective in October.
Like the layoffs, the reason for the recalls of some laid off CDER and Office of Chief Counsel staff remains unclear.
FTC under Chairman Andrew Ferguson is likely to be defined by less rules and guidance and a focus on enforcing laws already on the books, says BBB National Programs’ Exec VP, Policy, Mary Engle.
Foster, an advisor to the HHS Assistant Secretary for Preparedness and Response during the COVID-19 pandemic and counsel to the Senate HELP Committee, also served in various legal roles at small biotech companies. He replaces agency veteran Mark Raza.
Supplement industry trade groups and an attorney offer differing views of impact from layoffs imposed by White House’s “Department of Government Efficiency” reportedly numbering as many as 700. They agree layoffs, reported as some 700 across the agency with its food safety programs particularly hit, will affect FDA’s work, but not on whether it will be able to fulfill its responsibilities.
Some FDA employees who were recently laid off by the Trump Administration are being called back to work, multiple sources confirmed to the Pink Sheet.
As many as 700 employees reportedly dismissed from posts starting on 14 February as the culling of the federal workforce by the Trump administration’s Department of Government Efficiency reaches FDA.
Jim Jones resigna due to widespread layoffs at the agency the Trump administration’s Department of Government Efficiency imposed.
President Trump's Executive Order creating the commission names mental health and weight-loss drugs as treatments of concern. But it does not mention vaccines, which Kennedy has criticized.
Trade groups say they welcome working with Robert F. Kennedy Jr. on expanding and improving consumer access to OTC drugs and dietary supplements. White House “Department of Government Efficiency Workforce Optimization Initiative” limits filling federal agency vacancies.